Arrowhead Pharmaceuticals begins phase-1/2a study with ARO-ALK7 for the treatment of obesity
Breaking News: Arrowhead Pharmaceuticals Launches Phase 1/2a Study for Obesity Treatment In a groundbreaking development, Arrowhead Pharmaceutical, Inc. has announced the commencement of a Phase 1/2a clinical trial for ARO-ALK7, an RNA interference therapeutic aimed at combating obesity. This study marks a significant milestone in the quest for effective obesity treatments, leveraging cutting-edge RNA interference … Read more